肢端肥大症与高血压

基础医学与临床 ›› 2021, Vol. 41 ›› Issue (9): 1366-1370.

肢端肥大症与高血压

王书畅¹, 朱惠娟^2*, 潘慧^2,3*

1.河北医科大学第三医院内分泌一科, 河北石家庄 050051;
中国医学科学院北京协和医学院北京协和医院2.内分泌科国家卫生健康委员会内分泌重点实验室; 3.医务处, 北京 100730

收稿日期:2020-06-23 修回日期:2020-10-15 出版日期:2021-09-05 发布日期:2021-09-02
通讯作者: *panhui20111111@163.com; shengxin2004@163.com

Acromegaly and hypertension

WANG Shu-chang¹, ZHU Hui-juan^2*, PAN Hui^2,3*

1. Department of Endocrinology, the 3rd Hospital of Hebei Medical University, Shijiazhuang 050051;
2. Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology;3. Medical Department, Peking Union Medical College Hospital, CAMS & PUMC,Beijing 100730, China

Received:2020-06-23 Revised:2020-10-15 Online:2021-09-05 Published:2021-09-02
Contact: *panhui20111111@163.com; shengxin2004@163.com

摘要/Abstract

摘要： 肢端肥大症通常由分泌生长激素(GH)的垂体腺瘤引起,该疾病易并发或合并出现高血压,而高血压会加重患者的病情、增加疾病负担。本文旨在对肢端肥大症合并高血压的患病率、临床特点、病理生理学机制、诊断与治疗、肢端肥大症的疾病控制对其高血压的影响进行综述,以期加深对肢端肥大症合并高血压的认识、且对疾病防治提供依据。

关键词: 肢端肥大症, 高血压, 生长激素, 胰岛素样生长因子-1

Abstract: Acromegaly is usually caused by pituitary adenomas that secrete growth hormone (GH). The disease is prone to be complicated with hypertension and thus aggravates the state of the illness and increase the disease burden. This paper summarized the prevalence, clinical characteristics, pathophysiological mechanism, diagnosis and treatment of hypertension in patients with acromegaly and potential influence of the disease control on acromegaly on hypertension, in order to deepen the understanding of the disease and provide evidence for good prevention and control of hypertension in patients with acromegaly.

Key words: acromegaly, hypertension, growth hormone, insulin-like growth factor-1(IGF-1)

中图分类号:

王书畅, 朱惠娟, 潘慧. 肢端肥大症与高血压[J]. 基础医学与临床, 2021, 41(9): 1366-1370.

WANG Shu-chang, ZHU Hui-juan, PAN Hui. Acromegaly and hypertension[J]. Basic & Clinical Medicine, 2021, 41(9): 1366-1370.

参考文献

[1]Ritvonen E, Loyttyniemi E, Jaatinen P, et al. Mortality in acromegaly: a 20-year follow-up study[J]. Endocr Relat Cancer, 2016, 23: 469-480.
[2]Puglisi S, Terzolo M. Hypertension and acromegaly[J]. Endocrinol Metab Clin North Am, 2019, 48: 779-793.
[3]Minniti G, Moroni C, Jaffrain-Rea M L, et al. Prevalence of hypertension in acromegalic patients: clinical measurement versus 24-hour ambulatory blood pressure monitoring[J]. Clin Endocrinol (Oxf), 1998, 48: 149-152.
[4]Costenaro F, Martin A, Horn RF, et al. Role of ambulatory blood pressure monitoring in patients with acromegaly[J]. J Hypertens, 2016, 34: 1357-1363.
[5]Melmed S, Casanueva FF, Klibanski A, et al. A con-sensus on the diagnosis and treatment of acromegaly complications[J]. Pituitary, 2013, 16: 294-302.
[6]Terzolo M, Matrella C, Boccuzzi A, et al. Twenty-four hour profile of blood pressure in patients with acromegaly. Correlation with demographic, clinical and hormonal features[J]. J Endocrinol Invest, 1999, 22: 48-54.
[7]Sardella C, Urbani C, Lombardi M, et al. The beneficial effect of acromegaly control on blood pressure values in normotensive patients[J]. Clin Endocrinol (Oxf), 2014, 81: 573-581.
[8]Ramos-Levi AM, Marazuela M. Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management[J]. Endocrine, 2017, 55: 346-359.
[9]Arosio M, Reimondo G, Malchiodi E, et al. Predictors of morbidity and mortality in acromegaly: an Italian survey[J]. Eur J Endocrinol, 2012, 167: 189-198.
[10]Vitale G, Pivonello R, Auriemma RS, et al. Hyperten-sion in acromegaly and in the normal population: prevalence and determinants[J]. Clin Endocrinol (Oxf), 2005, 63: 470-476.
[11]Schutte AE, Volpe M, Tocci G, et al. Revisiting the relationship between blood pressure and insulin-like growth factor-1[J]. Hypertension, 2014, 63: 1070-1077.
[12]Powlson AS, Gurnell M. Cardiovascular disease and sleep-disordered breathing in acromegaly[J]. Neuroendocrinology, 2016, 103: 75-85.
[13]Sardella C, Cappellani D, Urbani C, et al. Disease activity and lifestyle influence comorbidities and cardiovascular events in patients with acromegaly[J]. Eur J Endocrinol, 2016, 175: 443-453.
[14]Kamenicky P, Blanchard A, Frank M, et al. Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity[J]. J Clin Endocrinol Metab, 2011, 96: 2127-2135.
[15]Thomas J, Dattani A, Zemrak F, et al. Renin-angioten-sin system blockade improves cardiac indices in acro-megaly patients[J]. Exp Clin Endocrinol Diabetes, 2017, 125: 365-367.
[16]Carmichael JD, Broder MS, Cherepanov D, et al. Long-term treatment outcomes of acromegaly patients presenting biochemically-uncontrolled at a tertiary pituitary center[J]. BMC Endocr Disord, 2017, 17: 49.doi:10.1186/s12902-017-0199-x.
[17]Gonzalez B, Vargas G, de Los MA, et al. Persistence of diabetes and hypertension after multimodal treatment of acromegaly[J]. J Clin Endocrinol Metab, 2018, 103: 2369-2375.
[18]Ioachimescu AG. Impact of acromegaly treatment on cardiovascular complications[J]. Endocrine, 2017, 55: 659-661.
[19]Auriemma RS, Grasso LF, Galdiero M, et al. Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly[J]. Endocrine, 2017, 55: 872-884.
[20]Annamalai AK, Webb A, Kandasamy N, et al. A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy[J]. J Clin Endocrinol Metab, 2013, 98: 1040-1050.
[21]Colao A. The GH-IGF-I axis and the cardiovascular system: clinical implications[J]. Clin Endocrinol (Oxf), 2008, 69: 347-358.
[22]Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study[J]. J Clin Endocrinol Metab, 2014, 99: 791-799.
[23]Kuhn E, Maione L, Bouchachi A, et al. Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study[J]. Eur J Endocrinol, 2015, 173: 693-702.
[24]Kasuki L, Vieira NL, Gadelha MR. Cabergoline treatment in acromegaly: cons[J]. Endocrine, 2014, 46: 220-225.
[25]Ntali G, Karavitaki N. Efficacy and complications of pituitary irradiation[J]. Endocrinol Metab Clin North Am, 2015, 44: 117-126.